Do we need oxytocin to treat schizophrenia? A randomized clinical trial

Jessica Dagani; Davide Sisti; Marianna Abelli; Luca Di Paolo; Stefano Pini; Sara Raimondi; Marco B. Rocchi; Francesco M. Saviotti; Paolo Scocco; Stefano Totaro; Matteo Balestrieri; Giovanni de Girolamo

doi:10.1016/j.schres.2016.02.011

Do we need oxytocin to treat schizophrenia? A randomized clinical trial

Jessica Dagani, Davide Sisti, Marianna Abelli, Luca Di Paolo, Stefano Pini, Sara Raimondi, Marco B. Rocchi, Francesco M. Saviotti, Paolo Scocco, Stefano Totaro, Matteo Balestrieri, Giovanni de Girolamo

Centro San Giovanni di Dio - Fatebenefratelli

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Schizophrenia is a disabling complex mental disorder and despite all available treatment, many patients unfortunately remain partial- or non-responders. A large body of research has shown that oxytocin is an important prosocial peptide and there is initial evidence that the central oxytocin system is altered in several mental disorders. The aim of this study was to test the efficacy of oxytocin, as augmentation therapy, in a sample of patients with schizophrenia. Methods: We conducted an 8-month randomized, double-blind, controlled trial with a crossover design. We wanted to test the hypothesis that intranasal oxytocin could reduce symptoms in 32 patients with schizophrenia aged 18-45 with short-medium illness duration (

Original language	English
Pages (from-to)	158-164
Journal	Schizophrenia Research
Volume	172
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2016.02.011
Publication status	Published - Apr 2016

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/j.schres.2016.02.011

Cite this

@article{2c33b4cb60c848a39b58c8174ad8815c,

title = "Do we need oxytocin to treat schizophrenia? A randomized clinical trial",

abstract = "Background: Schizophrenia is a disabling complex mental disorder and despite all available treatment, many patients unfortunately remain partial- or non-responders. A large body of research has shown that oxytocin is an important prosocial peptide and there is initial evidence that the central oxytocin system is altered in several mental disorders. The aim of this study was to test the efficacy of oxytocin, as augmentation therapy, in a sample of patients with schizophrenia. Methods: We conducted an 8-month randomized, double-blind, controlled trial with a crossover design. We wanted to test the hypothesis that intranasal oxytocin could reduce symptoms in 32 patients with schizophrenia aged 18-45 with short-medium illness duration (",

author = "Jessica Dagani and Davide Sisti and Marianna Abelli and {Di Paolo}, Luca and Stefano Pini and Sara Raimondi and Rocchi, {Marco B.} and Saviotti, {Francesco M.} and Paolo Scocco and Stefano Totaro and Matteo Balestrieri and {de Girolamo}, Giovanni",

year = "2016",

month = apr,

doi = "10.1016/j.schres.2016.02.011",

language = "English",

volume = "172",

pages = "158--164",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier B.V.",

number = "1-3",

}

TY - JOUR

T1 - Do we need oxytocin to treat schizophrenia? A randomized clinical trial

AU - Dagani, Jessica

AU - Sisti, Davide

AU - Abelli, Marianna

AU - Di Paolo, Luca

AU - Pini, Stefano

AU - Raimondi, Sara

AU - Rocchi, Marco B.

AU - Saviotti, Francesco M.

AU - Scocco, Paolo

AU - Totaro, Stefano

AU - Balestrieri, Matteo

AU - de Girolamo, Giovanni

PY - 2016/4

Y1 - 2016/4

N2 - Background: Schizophrenia is a disabling complex mental disorder and despite all available treatment, many patients unfortunately remain partial- or non-responders. A large body of research has shown that oxytocin is an important prosocial peptide and there is initial evidence that the central oxytocin system is altered in several mental disorders. The aim of this study was to test the efficacy of oxytocin, as augmentation therapy, in a sample of patients with schizophrenia. Methods: We conducted an 8-month randomized, double-blind, controlled trial with a crossover design. We wanted to test the hypothesis that intranasal oxytocin could reduce symptoms in 32 patients with schizophrenia aged 18-45 with short-medium illness duration (

AB - Background: Schizophrenia is a disabling complex mental disorder and despite all available treatment, many patients unfortunately remain partial- or non-responders. A large body of research has shown that oxytocin is an important prosocial peptide and there is initial evidence that the central oxytocin system is altered in several mental disorders. The aim of this study was to test the efficacy of oxytocin, as augmentation therapy, in a sample of patients with schizophrenia. Methods: We conducted an 8-month randomized, double-blind, controlled trial with a crossover design. We wanted to test the hypothesis that intranasal oxytocin could reduce symptoms in 32 patients with schizophrenia aged 18-45 with short-medium illness duration (

UR - http://www.scopus.com/inward/record.url?scp=84957895177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957895177&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2016.02.011

DO - 10.1016/j.schres.2016.02.011

M3 - Article

AN - SCOPUS:84957895177

VL - 172

SP - 158

EP - 164

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -

Do we need oxytocin to treat schizophrenia? A randomized clinical trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this